US20230172872A1

Use of an rxr agonist and taxanes in treating her2+ cancers

University of Texas System

Abstract

The present specification provides improved methods of treating Her2+ cancers in which an RXR agonist and a taxane are administered to a subject having a Her2+ cancer. Thyroid hormone and other anticancer agents may also be administered. Related compositions and combination are also disclosed

University: University of Texas System
Assignee: Board Of Regents, The University Of Texas System
Inventor: Martin E. Sanders
Priority date: December 07, 2021
Filing date: December 07, 2022
Publication date: June 08, 2023
Language: en
PDF source: https://patentimages.storage.googleapis.com/db/87/99/ff30b1f2418b84/US20230172872A1.pdf
Metadata fetched: August 29, 2026 00:31